Sign In
Buy CRL
$232.51
-2.11 (-0.90%)
At Close: Jul 31, 2026
SAN FRANCISCO , Dec. 17, 2025 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to mov
Charles River Laboratories International (NYSE:CRL) Reaches New 52-Week High Following Analyst Upgrade
01:29am, Tuesday, 16'th Dec 2025
Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) shares reached a new 52-week high on Monday after JPMorgan Chase and Co. raised their price target on the stock from $165.0
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO , Dec. 15, 2025 /PRNewswire/ -- Nat
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) Partner Reed Kathrein Scrutinizing Alleged Missta
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate CancerDrug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO , Dec. 11, 2025 /PRNewswire/ -- Nat
Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort
08:00am, Thursday, 11'th Dec 2025
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Laun
Federated Hermes Inc. Raises Stock Holdings in Charles River Laboratories International, Inc. $CRL
04:20am, Thursday, 11'th Dec 2025
Federated Hermes Inc. lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE: CRL) by 55,929.3% during the second quarter, according to the company in its most recent discl
Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO , Dec. 9, 2025 /PRNewswire/ -- Natio
Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) Partner Reed Kathrein Scrutinizes Alleged Misstate
Edgestream Partners L.P. Invests $1.80 Million in Charles River Laboratories International, Inc. $CRL
04:10am, Saturday, 06'th Dec 2025
Edgestream Partners L.P. purchased a new stake in Charles River Laboratories International, Inc. (NYSE: CRL) in the second quarter, according to its most recent disclosure with the Securities and Exch
Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO , Dec. 5, 2025 /PRNewswire/ -- Natio
Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) Partner Reed Kathrein Scrutinizes Alleged Misstate
T. Rowe Price Transitions to Charles River's Enterprise Multi-Asset Investment Management Platform
08:30am, Thursday, 04'th Dec 2025
BOSTON--(BUSINESS WIRE)--Charles River Development, a State Street Company, announced today the expansion of its relationship with T. Rowe Price through the migration to the SaaS-deployed Charles Rive
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Recommendation of “Moderate Buy” from Brokerages
01:57am, Thursday, 04'th Dec 2025
Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) has received an average recommendation of "Moderate Buy" from the eighteen ratings firms that are covering the company, Mar
Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO , Dec. 3, 2025 /PRNewswire/ -- Natio
